IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.
Cancer Cell
; 27(3): 323-5, 2015 Mar 09.
Article
en En
| MEDLINE
| ID: mdl-25759018
ABSTRACT
There is a pressing need to develop novel, mechanism-based therapeutic approaches that can be used to improve therapies for genetically defined tumor subtypes. Chan and colleagues have demonstrated recently that BCL-2 inhibitors can target IDH1/2 mutant cancers through a mutant-specific dependency in metabolic regulation.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Sulfonamidas
/
Leucemia Mieloide Aguda
/
Resistencia a Antineoplásicos
/
Compuestos Bicíclicos Heterocíclicos con Puentes
/
Proteínas Proto-Oncogénicas c-bcl-2
/
Isocitrato Deshidrogenasa
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Cancer Cell
Asunto de la revista:
NEOPLASIAS
Año:
2015
Tipo del documento:
Article
País de afiliación:
Estados Unidos